Abstract
Background Incidences of colon and rectal cancers have been parallelly and constantly increased, however, the mortality has been slightly decreased due to early diagnosis and better therapies during the last decades. Precise early diagnosis for colorectal cancer has been a great challenge in order to win chances for the best choices of cancer therapies.
Patients and methods We have started with searching protein biomarkers based on our colorectal biomarker database (CBD), finding differential expressed genes (GEGs) and non-DEGs from RNA sequencing (RNA-seq) data, and further predicted new biomarkers on protein-protein interaction (PPI) networks by machine learning (ML) methods. The best-selected biomarker was further verified by receiver operating characteristic (ROC) test from microarray and RNA-seq data, biological network and functional analysis, and immunohistochemistry in the tissue arrays from 198 specimens.
Results There were twelve proteins (MYO5A, CHGA, MAPK13, VDAC1, CCNA2, YWHAZ, CDK5, GNB3, CAMK2G, MAPK10, SDC2, and ADCY5) which were predicted by ML as colon cancer candidate diagnosis biomarkers. These predicted biomarkers showed close relationships with reported biomarkers on PPI network and shared some pathways. ROC test showed CHGA protein with the best diagnostic accuracy (AUC=0.9 in microarray data and 0.995 in RNA-seq data) among these candidate protein biomarkers. Furthermore, CHGA performed well in the immunohistochemistry test.
Conclusions Protein expression of CHGA in the normal colorectal mucosa was lost in the colorectal cancers and the lose of CHGA protein might be a potential candidate biomarker for colon or even colorectal cancer diagnosis.
Topic CHGA expression, colon cancer diagnosis
Key Message The results of this study suggest that lose of CHGA expression from the normal colon and adjacent mucosa to colon cancer may be used as a valuable biomarker for early diagnosis of colon adenocarcinoma
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the institutional review board of Linkoping University, Sweden (Dnr-2012-107-31, Dnr 2014-79-31).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
